Mexiprim tablets 125mg, No. 30

• Consequences of acute disorders of cerebral circulation, including after transient ischemic attacks, in the phase of subcompensation as preventive courses;

• Minor traumatic brain injury, consequences of traumatic brain injury;

• Encephalopathy of various origins (discirculatory, dysmetabolic, post-traumatic, mixed);

• Autonomic dystonia syndrome;

• Mild cognitive disorders of atherosclerotic genesis;

• Anxiety disorders in neurotic and neurosis-like states;

• Ischemic heart disease as part of complex therapy;

• Relief of withdrawal symptoms in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders, post-withdrawal disorders;

• Conditions after acute intoxication with antipsychotic drugs;

• Asthenic conditions, as well as for the prevention of the development of somatic diseases under the influence of extreme factors and loads;

• Exposure to extreme (stress) factors.

Inside. 125-250 mg (1-2 tablets) 3 times a day. The initial dose is 125-250 mg (1-2 tablets) 1-2 times a day with a gradual increase until a therapeutic effect is obtained. The maximum daily dose is 750 mg (6 tablets). Duration of treatment is 2-6 weeks; for relief of alcohol withdrawal - 5-7 days. The duration of the course of therapy in patients with ischemic heart disease is at least 1.5Ц2 months. The treatment is stopped gradually, reducing the dose within 2-3 days. Repeated courses (on the recommendation of a doctor), preferably in the spring and autumn periods.

One tablet contains:

active substance: ethylmethylhydroxypyridine succinate 125 mg;

excipients: kaolin, sodium carboxymethyl starch, microcrystalline cellulose, povidone K 17, talc, calcium stearate; excipients (shell): hypromellose, macrogol, titanium dioxide, talc.

• Acute violations of liver and kidney function,

• hypersensitivity to the active substance and other components of the drug.

• Due to insufficient knowledge of the effect of the drug - children's age, pregnancy, breastfeeding.

Pharmacodynamics:
Mexiprim is a 3-hydroxypyridine derivative; has antioxidant, antihypoxic, anti-ischemic, membrane-protective, nootropic, stress-protective, anticonvulsant, anxiolytic, hypolipidemic action. The mechanism of action of the drug is due to antioxidant, antihypoxant and membrane-protective effects. Mexiprim reduces the manifestations of oxidative stress, inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, improves the structure and function of the cell membrane. The drug modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, gamma-aminobutyric acid (GABA), acetylcholine), which enhances their ability to bind to ligands,contributes to the preservation of the structural and functional organization of biomembranes, the transport of neurotransmitters and the improvement of synaptic transmission. Mexiprim increases the content of dopamine in the brain. It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under conditions of hypoxia with an increase in the content of adenosine triphosphate (ATP) and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, stabilization of cell membranes. The drug has a wide spectrum of pharmacological activity; increases the body's resistance to stress and the effects of various damaging factors in pathological conditions (hypoxia and ischemia, cerebrovascular accident, intoxication with ethanol and antipsychotic drugs).transport of neurotransmitters and improve synaptic transmission. Mexiprim increases the content of dopamine in the brain. It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of adenosine triphosphate (ATP) and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, stabilization of cell membranes. The drug has a wide spectrum of pharmacological activity; increases the body's resistance to stress and the effects of various damaging factors in pathological conditions (hypoxia and ischemia, cerebrovascular accident, intoxication with ethanol and antipsychotics).transport of neurotransmitters and improve synaptic transmission. Mexiprim increases the content of dopamine in the brain. It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of adenosine triphosphate (ATP) and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, stabilization of cell membranes. The drug has a wide spectrum of pharmacological activity; increases the body's resistance to stress and the effects of various damaging factors in pathological conditions (hypoxia and ischemia, cerebrovascular accident, intoxication with ethanol and antipsychotics).It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of adenosine triphosphate (ATP) and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, stabilization of cell membranes. The drug has a wide spectrum of pharmacological activity; increases the body's resistance to stress and the effects of various damaging factors in pathological conditions (hypoxia and ischemia, cerebrovascular accident, intoxication with ethanol and antipsychotic drugs).It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of adenosine triphosphate (ATP) and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, stabilization of cell membranes. The drug has a wide spectrum of pharmacological activity; increases the body's resistance to stress and the effects of various damaging factors in pathological conditions (hypoxia and ischemia, cerebrovascular accident, intoxication with ethanol and antipsychotics).The drug has a wide range of pharmacological activity; increases the body's resistance to stress and the effects of various damaging factors in pathological conditions (hypoxia and ischemia, cerebrovascular accident, intoxication with ethanol and antipsychotic drugs).The drug has a wide range of pharmacological activity; increases the body's resistance to stress and the effects of various damaging factors in pathological conditions (hypoxia and ischemia, cerebrovascular accident, intoxication with ethanol and antipsychotic drugs).
The drug has a wide range of pharmacological activity; increases the body's resistance to stress and the effects of various damaging factors in pathological conditions (hypoxia and ischemia, cerebrovascular accident, intoxication with ethanol and antipsychotic drugs).
Improves the functional state of the ischemic myocardium. In conditions of coronary insufficiency, it increases collateral blood supply to the ischemic myocardium, contributes to the preservation of the integrity of cardiomyocytes and the maintenance of their functional activity. Effectively restores myocardial contractility in reversible cardiac dysfunction.
Improves the metabolism of brain tissue and their blood supply, improves microcirculation and rheological properties of blood, reduces platelet aggregation. It stabilizes the membrane structures of blood cells (erythrocytes and platelets). It has a hypolipidemic effect, reduces the content of total cholesterol and low density lipoproteins.
Shows anxiolytic effect, not accompanied by a muscle relaxant effect; possesses nootropic properties, prevents and reduces learning and memory impairments that occur during aging and exposure to various pathogenic factors; has an anticonvulsant effect; increases concentration and performance.
The antistress effect is manifested in the normalization of post-stress behavior, somatovegetative disorders, restoration of sleep-wakefulness cycles, impaired learning and memory processes, reduction of dystrophic and morphological changes in various structures of the brain.
Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.
Has a pronounced antitoxic effect in withdrawal symptoms. Eliminates neurological and neurotoxic manifestations of acute alcohol intoxication, restores behavioral disorders, autonomic functions, helps to reduce the severity of cognitive impairments caused by prolonged intake of ethanol. Under the influence of the drug, the effect of tranquilizing, neuroleptic, antidepressant, hypnotics and anticonvulsants is enhanced, which makes it possible to reduce their doses and reduce side effects.

Pharmacokinetics:
It is rapidly absorbed when taken orally. The maximum concentration (Cmax) at doses of 400-500 mg is 3.5-4.0 ?g / ml. It is quickly distributed in organs and tissues. The average retention time of the drug in the body (MRT) when taken orally is 4.9-5.2 hours. It is metabolized in the liver by glucuron conjugation. 5 metabolites identified: 3-hydroxypyridine phosphate? it is formed in the liver, with the participation of alkaline phosphatase it breaks down into phosphoric acid and 3-hydroxypyridine; 2nd metabolite? pharmacologically active, is formed in large quantities and is found in the urine 1-2 days after administration; 3rd? excreted in large quantities in the urine; 4th and 5th? glucuron conjugates. The half-life (T1 / 2) when taken orally is 2.0-2.6 hours. Is it quickly excreted in the urine, mainly in the form of metabolites and in an insignificant amount? unchanged.The most intensively excreted during the first 4 hours after taking the drug. The indicators of excretion in the urine of unchanged drug and metabolites have individual variability.

Side effects:
Rarely - nausea, dryness of the oral mucosa, drowsiness, allergic reactions.

Special instructions:
During the period of treatment, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.

Interaction with other drugs:
Mexiprim is compatible with all drugs used to treat somatic diseases. Strengthens the effect of benzodiazepine drugs, antidepressants, anxiolytics, antiepileptic drugs (carbamazepine) and antiparkinsonian drugs (levodopa), nitrates. Reduces the toxic effect of ethanol.